Korea reinstates market approval of sibutramine

Published: 2010-07-22 06:59:00

Updated: 2010-07-22 06:59:00

The Korean Food and Drug Administration said on July 20 it has concluded that the benefit/risk assessment of sibutramine is favorable and will its continued sale here after convening the Central Pharmaceutical Affairs Review Committee meeting on July 19 to discuss the drug's benefit/risk profile ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK